Skip to main content

Opko Health (OPK) Has a New Rating from Ladenburg Thalmann & Co.

Tipranks - Tipranks - Fri Jul 11, 2025

Opko Health received a Buy rating and a $5.20 price target from Ladenburg Thalmann & Co. analyst Kevin DeGeeter on July 8. The company’s shares opened today at $1.37.

Elevate Your Investing Strategy:

DeGeeter covers the Healthcare sector, focusing on stocks such as Opko Health, Cardiff Oncology, and NovoCure. According to TipRanks, DeGeeter has an average return of 20.3% and a 38.68% success rate on recommended stocks.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Opko Health with a $2.44 average price target.

See the top stocks recommended by analysts >>

Based on Opko Health’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $149.95 million and a GAAP net loss of $67.61 million. In comparison, last year the company earned a revenue of $173.69 million and had a GAAP net loss of $81.84 million

Read More on OPK:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).